26
|
Bakar S, Hayman S, McCarty D, Thain A, McLellan A, Wagner C, Lavi S. INVASIVE ASSESSMENT OF MICROVASCULAR RESISTANCE IN HYPERTROPHIC CARDIOMYOPATHY WITH ECHOCARDIOGRAPHIC CORRELATES. Can J Cardiol 2019. [DOI: 10.1016/j.cjca.2019.07.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
27
|
Sidiqi M, Saleh AA, Kumar S, Morie G, Dispenzieri A, Buadi F, Lacy M, Leung N, Muchtar E, Kyle R, Go R, Hobbs M, Gonsalves W, Kourelis T, Warsame R, Dingli D, Lust J, Hayman S, Rajkumar V, Kapoor P. PS1422 VENETOCLAX FOR THE TREATMENT OF MULTIPLE MYELOMA: OUTCOMES OUTSIDE OF CLINICAL TRIALS. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000563964.92802.c3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
28
|
Grieb B, Abeykoon J, Zanwar S, Rajkumar S, Lacy M, Dispenzieri A, Gertz M, Gonsalves W, Go R, Buadi F, Dingli D, Hayman S, Warsame R, Kourelis T, Muchtar E, Kyle R, Kumar S, Kapoor P. PS1397 OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000563864.43294.ef] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
29
|
Matthews A, Sidana S, Seymour L, Pick N, Pringnitz J, Argue D, Lange G, Brandes E, McClanahan A, Nedved A, Hayman S, Kenderian S, Kumar S, Dingli D, Kourelis T, Warsame R, Kapoor P, Shah M, Alkhateeb H, Johnston P, Ansell S, Bennani N, Siddiqui M, Lin Y. QIM19-136: Developing an Ideal CAR-T Cell Therapy Patient Experience Through Human-Centered Design and Innovation. J Natl Compr Canc Netw 2019. [DOI: 10.6004/jnccn.2018.7187] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background: The patient/caregiver experience during CAR-T therapy is stressful, overwhelming, terrifying, and often a patient’s last treatment option. The Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Innovation and Design team has worked with the CAR-T therapy clinical team to develop a patient experience that provides patients with a sense of caring, supportive environment, timely knowledge, and realistic expectations. Using a human-centered design approach, the Innovation and Design team worked with patients and caregivers to understand latent and unspoken needs in order to develop an ideal CAR-T therapy patient journey. Methods: With qualitative interviewing techniques, patient observation, and low fidelity experimentation, 21 patients/caregiver pairs were interviewed throughout their CAR-T therapy experience in 2018. Patients were interviewed at several touch points as well as encouraged to reach out to the Innovation and Design team at any point with reflections on their experiences. Patients were recruited as they began their evaluation phase for CAR-T therapy. The interviews were unscripted to allow for a breadth of discovery by not constraining the conversations to previously developed themes. As themes emerged from patient/caregiver interviews, artifacts and interventions were designed to alleviate pain points and improve the patient/caregiver experience. These artifacts and interventions were integrated into the clinical processes in real time and patient/caregivers were interviewed to understand the impact of these activities. Results: Several themes emerged from qualitative interviews with patients and caregivers. From the themes, interventions were developed. We were able to demonstrate a qualitative improvement in patient/caregiver experience through these interventions (Figure 1). Conclusions: Patients/caregivers undergoing CAR-T therapy have unique issues surrounding the logistics of care, emotional burden, and physical effects of treatment. We implemented processes to address these issues and observed a qualitative improvement via patient interviews/feedback. Ongoing work includes optimizing remote monitoring, digital platforms for patient education, and a quantitative study looking at patient reported outcomes (PROs) in such patients. To our knowledge, this is the first report for care delivery optimization in real-world practice for this new therapy.
Collapse
|
30
|
Hayman S, LaPlant B, Buadi F, Asmus EJ, Kapoor P, Lacy M, Dingli D, Dispenzieri A, Kourelis T, Warsame R, Gonsalves WI, Muchtar E, Miceli T, Hogan WJ, Gertz M, Kumar S. Phase 1/2 Trial of Carfilzomib and Melphalan Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL). Biol Blood Marrow Transplant 2019. [DOI: 10.1016/j.bbmt.2018.12.102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Tschautscher M, Rajkumar V, Dispenzieri A, Lacy M, Gertz M, Buadi F, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Zeldenrust S, Lust J, Russell S, Leung N, Kapoor P, Go R, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle R, Kumar S. Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. Am J Hematol 2018; 93:1207-1210. [PMID: 30016549 DOI: 10.1002/ajh.25215] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Accepted: 07/10/2018] [Indexed: 11/10/2022]
Abstract
Detection of myeloma progression (PD) relies on serial 24-h urinary M protein measurements in patients without measurable serum M spike. We examined whether serial difference free light chain (dFLC) levels could be used as a surrogate for serial 24-h urine M protein measurements in monitoring for PD in patients with baseline measurable urine M protein. We studied 122 patients who had serial measurement of urine M protein and serum FLC and had demonstrated PD. The median increase in dFLC with progression as defined by urine M spike was 110% (IQR: 55-312) and median absolute increase was 74 mg/dL; while 89% of patients had dFLC increase ≥ 25%, 94% had absolute increase in dFLC > 10 mg/dL, and 98% met at least 1 of these 2 criteria at PD. In patients with baseline measurable serum FLC (n = 118), 89% had increase in dFLC ≥ 25%, 97% had dFLC increase of > 10 mg/dL, and 98% had 1 of the 2. We conclude that serial dFLC assessments can be used in place of serial 24-h urine protein assessments during myeloma surveillance to monitor for PD. Once patients have an absolute increase in dFLC of >10 mg/dL from the nadir, a 24-h urine collection can then be assessed to document PD as per the International Myeloma Working Group criteria.
Collapse
|
32
|
Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol 2018; 97:1417-1425. [DOI: 10.1007/s00277-018-3311-z] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Accepted: 03/19/2018] [Indexed: 12/31/2022]
|
33
|
Paludo J, Abeykoon JP, Kapoor P, Kumar S, Gertz M, Hayman S, Buadi F, Dispenzieri A, Lust JA, Leung N, Dingli D, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Lacy MQ, Kyle R, Rajkumar SV, Go RS. Characterization of Long-Term Multiple Myeloma Survivors. Biol Blood Marrow Transplant 2018. [DOI: 10.1016/j.bbmt.2017.12.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Tomlinson S, Jayasuria T, Hayman S, Stewart P. A Bleeding Heart. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jelicic J, Hayman S, Mihaljevic B. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol 2016; 91:1014-9. [PMID: 27380861 DOI: 10.1002/ajh.24466] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Revised: 06/29/2016] [Accepted: 07/01/2016] [Indexed: 12/22/2022]
Abstract
Lymphoma patients are at increased risk of thromboembolic events but thromboprophylaxis in these patients is largely underused. We sought to develop and validate a simple model, based on individual clinical and laboratory patient characteristics that would designate lymphoma patients at risk for thromboembolic event. The study population included 1,820 lymphoma patients who were treated in the Lymphoma Departments at the Clinics of Hematology, Clinical Center of Serbia and Clinical Center Kragujevac. The model was developed using data from a derivation cohort (n = 1,236), and further assessed in the validation cohort (n = 584). Sixty-five patients (5.3%) in the derivation cohort and 34 (5.8%) patients in the validation cohort developed thromboembolic events. The variables independently associated with risk for thromboembolism were: previous venous and/or arterial events, mediastinal involvement, BMI>30 kg/m(2) , reduced mobility, extranodal localization, development of neutropenia and hemoglobin level < 100g/L. Based on the risk model score, the population was divided into the following risk categories: low (score 0-1), intermediate (score 2-3), and high (score >3). For patients classified at risk (intermediate and high-risk scores), the model produced negative predictive value of 98.5%, positive predictive value of 25.1%, sensitivity of 75.4%, and specificity of 87.5%. A high-risk score had positive predictive value of 65.2%. The diagnostic performance measures retained similar values in the validation cohort. Developed prognostic Thrombosis Lymphoma - ThroLy score is more specific for lymphoma patients than any other available score targeting thrombosis in cancer patients. Am. J. Hematol. 91:1014-1019, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
|
36
|
Grogan M, Gertz M, McCurdy A, Roeker L, Kyle R, Kushwaha S, Daly R, Dearani J, Rodeheffer R, Frantz R, Lacy M, Hayman S, McGregor C, Edwards B, Dispenzieri A. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant 2016; 6:380-388. [PMID: 27358783 PMCID: PMC4919742 DOI: 10.5500/wjt.v6.i2.380] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Revised: 03/14/2016] [Accepted: 04/11/2016] [Indexed: 02/05/2023] Open
Abstract
AIM: To determine the outcome of orthotopic heart transplantation (OHT) in immunoglobulin light chain (AL) amyloidosis.
METHODS: The medical records of patients with AL who underwent orthotopic heart transplantation at the Mayo Clinic in Rochester Minnesota from 1992 to 2011 were reviewed. Patients met at least one of the following at: New York Heart Association class IV heart failure, ventricular thickness > 15 mm, ejection fraction < 40%. Selection guidelines for heart transplant included age < 60 years, absence of multiple myeloma and significant extra-cardiac organ involvement. Baseline characteristics including age, gender, organ involvement, and New York Heart Association functional class were recorded. Laboratory data, waiting time until heart transplant, and type of treatment of the underlying plasma cell disorder were recorded. Survival from the time of OHT was calculated using Kaplan-Meier survival curves. Survival of patients undergoing OHT for AL was compared to that of non-amyloid patients undergoing OHT during the same time period.
RESULTS: Twenty-three patients (median age 53 years) with AL received OHT. There were no deaths in the immediate perioperative period. Twenty patients have died post OHT. For the entire cohort, the median overall survival was 3.5 years (95%CI: 1.2, 8.2 years). The 1-year survival post OHT was 77%, the 2-year survival 65%, and the 5-year survival 43%. The 5-year survival for non-amyloid patients undergoing OHT during the same era was 85%. Progressive amyloidosis contributed to death in twelve patients. Of those without evidence of progressive amyloidosis, the cause of death included complications of autologous hematopoietic stem cell transplantation for 3 patients, post-transplant lymphoproliferative disorder for 2 patients; and for the remaining one death was related to each of the following causes: acute rejection; cardiac vasculopathy; metastatic melanoma; myelodysplastic syndrome; and unknown. Eight patients had rejection at a median of 1.8 mo post OHT (range 0.4 to 4.9 mo); only one patient died of rejection. Median survival of seven patients who achieved a complete hematologic response to either chemotherapy or autologous hematopoietic stem cell transplantation was 10.8 years.
CONCLUSION: Our data demonstrate that long term survival after heart transplant is feasible in AL patients with limited extra-cardiac involvement who achieve complete hematologic response.
Collapse
|
37
|
Paludo J, Gertz M, Ansell S, Abeykoon JP, Dispenzieri A, Lacy MQ, Kyle R, Buadi F, Dingli D, Hayman S, Gonsalves WI, Rajkumar SV, Kumar S, Kapoor P. Impact of Day-100 Response Post Autologous Stem Cell Transplantation (ASCT) in Waldenström Macroglobulinemia (WM). Biol Blood Marrow Transplant 2016. [DOI: 10.1016/j.bbmt.2015.11.461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
38
|
Gonsalves WI, Gertz M, Dispenzieri A, Lacy M, Buadi F, Dingli D, Hayman S, Kapoor P, Rajkumar SV, Kumar S. Predictors of Survival in Multiple Myeloma Patients after Relapse from a Delayed Autologous Stem Cell Transplant. Biol Blood Marrow Transplant 2015. [DOI: 10.1016/j.bbmt.2014.11.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Nam M, Nel K, Hayman S, Chacko Y, Lau K, Senior R, Greaves K. Myocardial blood flow assessment in cardiac amyloidosis using myocardial contrast echocardiography. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.06.561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
40
|
|
41
|
Chacko Y, Hayman S, Willson A, Butterly S, Larsen P, Poulter R, Thompson C, Colburn D, Lau K, Johnson M. Utility of a new regional cardiac catheterisation laboratory. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.06.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Hayman S, Colburn D, Greaves K, Larsen P, Poulter R, Butterly S, Chako Y, Lau K, Nam M, Thompson C, Willson A. Out-of-hospital Cardiac Arrest (OOHCA) referred for Primary Percutaneous Coronary Intervention (PPCI): Results in a regional setting. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.06.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Peverill W, Hayman S, Brazzale A, Puchalski R, Stewart P, Dooris M. Percutaneous coronary intervention in the very elderly. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.06.421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
44
|
Ghobrial IM, Witzig TE, Gertz M, LaPlant B, Hayman S, Camoriano J, Lacy M, Bergsagel PL, Chuma S, DeAngelo D, Treon SP. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol 2014; 89:237-42. [PMID: 24716234 DOI: 10.1002/ajh.23620] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Everolimus is an oral raptor mTOR inhibitor and has shown activity in patients with Waldenstrom's macroglobulinemia (WM). This study examines a large cohort of patients with relapsed/refractory WM with long-term follow up for survival. Patients were eligible if they had measurable disease, a platelet count >75,000 x 10(6)/L, an absolute neutrophil count >1,000 x 10(6)/L. Patients received everolimus 10 mg PO daily and were evaluated monthly. A success was defined as a complete or partial response (PR); minor responses (MR) were recorded and considered to be of clinical benefit. Sixty patients were enrolled and treated. The overall response rate (ORR) was 50% (all PR); the clinical benefit rate including MR or better was 73% (95% CI: 60-84%) with 23% MR. The median time to response for patients who achieved PR was 2 months (range, 1-26). The median duration of response has not been reached and median progression-free survival (PFS) was 21 months. Grade 3 or higher toxicities (at least possibly related to everolimus) were observed in 67% of patients. The most common grade 3 or 4 toxicities were anemia (27%), leukopenia (22%), and thrombocytopenia (20%). Other nonhematological toxicities were diarrhea (5%), fatigue (8%), stomatitis (8%) and pulmonary toxicity (5%). Everolimus has a high single-agent activity of 73% including MR, with a progression free survival of 21 months, indicating that this agent is active in relapsed/refractory WM.
Collapse
|
45
|
Meads C, Nyssen OP, Wong G, Steed L, Bourke L, Ross CA, Hayman S, Field V, Lord J, Greenhalgh T, Taylor SJC. Protocol for an HTA report: Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic modelling. BMJ Open 2014; 4:e004377. [PMID: 24549165 PMCID: PMC3932001 DOI: 10.1136/bmjopen-2013-004377] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
INTRODUCTION Long-term medical conditions (LTCs) cause reduced health-related quality of life and considerable health service expenditure. Writing therapy has potential to improve physical and mental health in people with LTCs, but its effectiveness is not established. This project aims to establish the clinical and cost-effectiveness of therapeutic writing in LTCs by systematic review and economic evaluation, and to evaluate context and mechanisms by which it might work, through realist synthesis. METHODS Included are any comparative study of therapeutic writing compared with no writing, waiting list, attention control or placebo writing in patients with any diagnosed LTCs that report at least one of the following: relevant clinical outcomes; quality of life; health service use; psychological, behavioural or social functioning; adherence or adverse events. Searches will be conducted in the main medical databases including MEDLINE, EMBASE, PsycINFO, The Cochrane Library and Science Citation Index. For the realist review, further purposive and iterative searches through snowballing techniques will be undertaken. Inclusions, data extraction and quality assessment will be in duplicate with disagreements resolved through discussion. Quality assessment will include using Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. Data synthesis will be narrative and tabular with meta-analysis where appropriate. De novo economic modelling will be attempted in one clinical area if sufficient evidence is available and performed according to the National Institute for Health and Care Excellence (NICE) reference case.
Collapse
|
46
|
Keyzner A, D'Souza A, Lacy M, Gertz M, Hayman S, Buadi F, Kumar S, Dingli D, Engebretson A, Tong C, Dispenzieri A. Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. Biol Blood Marrow Transplant 2013; 19:1395-8. [PMID: 23792270 DOI: 10.1016/j.bbmt.2013.06.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Accepted: 06/13/2013] [Indexed: 12/28/2022]
Abstract
A rare, multisystem, plasma cell neoplasm, POEMS (polyradiculoneuropathy, organomegaly, endocrinopathy, M-spike, skin changes) syndrome is characterized by an abundance of proinflammatory and angiogenic cytokines. Patients with POEMS are known to have a high incidence of engraftment syndrome after autologous stem cell transplantation. We conducted a pilot study assessing levels of 30 different pro- and anti-inflammatory cytokines before and serially after transplantation in 18 patients with plasma cell neoplasms: POEMS syndrome (n = 9), multiple myeloma (n = 4), and amyloidosis (n = 5). We show that POEMS patients have higher pretransplantation levels of IL-4, IL-10, IL-13, IFN-α, and EGF as compared with those with non-POEMS plasma cell neoplasms. Higher pre- and posttransplantation IL-13 levels correlated with delayed neutrophil engraftment in POEMS patients. Low posttransplantation IL-1RA levels correlated with engraftment syndrome in both POEMS and non-POEMS patients. We conclude that differences in the peri-transplantation cytokine milieu may explain the higher transplantation morbidity in patients with POEMS syndrome. Our results need validation in a larger cohort.
Collapse
|
47
|
Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, Kumar S, Leung N, Dingli D, Dispenzieri A. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2013; 88:375-8. [PMID: 23508840 DOI: 10.1002/ajh.23413] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2012] [Revised: 01/26/2013] [Accepted: 02/07/2013] [Indexed: 12/22/2022]
Abstract
To clarify the presentation and course of patients with chronic lymphocytic leukemia (CLL) and amyloidosis. Mayo databases were interrogated for patients who carried a diagnosis of amyloidosis and CLL evaluated at Mayo Clinic, Rochester from January 1974 to October 2012. Charts were abstracted and data analyzed. Of the 33 patients identified, 20 (61%) were diagnosed with AL and 13 (39%) with non-AL. Only four patients had immunoglobulin light chain amyloidosis (AL) that could be solely attributed to the CLL clone; another six had both a plasma cell clone and a CLL clone that shared the same light chain. Median overall survival was 15.6 months for patients with AL and 58.1 months for patients with non-AL. For patients with AL management involved chemotherapy targeted toward monoclonal plasma cells, lymphocytes or both, and for patients with non-AL no specific amyloid treatment was administered. AL is a rare complication of CLL, but in this elderly population of patients non-AL is nearly as common. Distinguishing between these two groups is essential since patients with non-AL amyloidosis have better outcomes and they do not require cytotoxic chemotherapy to treat their amyloidosis.
Collapse
|
48
|
Smeltzer J, Gertz M, Rajkumar SV, Dispenzieri A, Lacy M, Buadi F, Hayman S, Dingli D, Kapoor P, Kumar S. Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma. Biol Blood Marrow Transplant 2013. [DOI: 10.1016/j.bbmt.2012.11.115] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Burnette BL, Gertz M, Kumar S, Lacy M, Buadi F, Hayman S, Dingli D, Inwards DJ, Johnston PB, Micallef IN, Porrata LF, Hogan W, Litzow MR, Patnaik M, Hashmi S, Leung N, Afessa B, Gastineau D, Ansell SM, Holtan S, Dispenzieri A. Redefining Engraftment Syndrome: The New Mayo Clinic Criteria. Biol Blood Marrow Transplant 2013. [DOI: 10.1016/j.bbmt.2012.11.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
50
|
Puchalski R, Peverill W, Brazzale A, Hayman S, Dooris M, Stewart P. Outcomes of Percutaneous Coronary Intervention in a Nonagenarian Population. Heart Lung Circ 2013. [DOI: 10.1016/j.hlc.2013.05.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|